Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Ipilimumab in advanced NSCLC
NCT03001882Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2017
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Mar 2017; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03001882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03001882.